pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Nephrology · news · pharmadog
← back to Nephrology
News · Nephrology
282
stories
15d
STAT+: A closer look at ProMis Neurosciences and its Alzheimer’s drug
stat
15d
Cash-strapped Vivoryon regains China rights to kidney disease prospect from Simcere
fiercebiotech
17d
Vertex, ahead of FDA decision, calms fears surrounding kidney drug
biopharma dive
17d
STAT+: Who will get the first psychedelic approved?
stat
17d
Abbott's Tectonic test looks to shift artery disease treatment with ‘early’ win
fiercebiotech
18d
STAT+: Psilocybin’s lasting benefits prove elusive in mice
stat
18d
STAT+: Coming readout of Kymera eczema trial is a high-stakes moment in a bid to rival Dupixent
stat
18d
Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdict
biospace
21d
This week in charts: ESMO’s winners and losers
biopharma dive
22d
STAT+: El-Sayed claps back at RFK Jr., and FDA’s ‘enforcement discretion’ on peptides
stat
22d
STAT+: HHS green lights six peptides, despite concerns from FDA scientists
stat
22d
STAT+: Vertex kidney disease drug scrutinized for infection risk
stat
22d
Use Kidney Genetics to Strengthen Clinical Trial Design
fiercebiotech
22d
Merck outlines 2027 as ‘another year of investment’ despite recent clinical wins
fiercebiotech
22d
BioMarin inks up to $475M deal to challenge Fabry ERT incumbents
fiercebiotech
23d
Oura, UC San Diego Health collaborate to study GLP-1 outcomes using continuous smart ring data
fiercebiotech
23d
Biogen set up for growth even without M&A but CEO won’t rule it out
biospace
23d
Biogen CEO tells analysts he’s focused on early-stage R&D as ‘we were not very good with that’
fiercebiotech
25d
ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data
biopharma dive
25d
ESMO 2026: Analysts warm to Merck, Moderna’s cancer vaccine after frustrating data leak
biospace
27d
‘It is what it is’: Merck exec unruffled by ‘unfortunate’ leak of ESMO cancer vaccine data
fiercebiotech
28d
Roche puts numbers behind phase 3 kidney disease win amid blockbuster ambitions
fiercebiotech
29d
ESMO 2026: Merck, Moderna shares fall as cancer vaccine disappoints after data leak
biospace
29d
Moderna, Merck shares fall on eagerly anticipated cancer vaccine results
biopharma dive
29d
Looking Beyond the First Answer Towards Delivering Impact
fiercebiotech
29d
Why investors are taking another look at kidney disease
biospace
29d
Celltrion picks up another Kaigene autoimmune antibody for up to $580.5M
fiercebiotech
Oct 21, 26
Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal
biopharma dive
Oct 21, 26
GSK, Ionis win FDA nod for hepatitis B functional cure that controls virus after treatment
biospace
Oct 20, 26
FDA Approves First-of-Its-Kind Chronic Hepatitis B Treatment
fda press
← prev
page 2 of 10
next →